MCID: BLD051
MIFTS: 52

Blood Coagulation Disease

Categories: Blood diseases

Aliases & Classifications for Blood Coagulation Disease

MalaCards integrated aliases for Blood Coagulation Disease:

Name: Blood Coagulation Disease 12 15 17
Blood Coagulation Disorders 73 44 70
Postpartum Coagulation Defect with Delivery 12
Inherited Blood Coagulation Disease 12
Postpartum Coagulation Defect 12
Coagulation Protein Disorders 70
Coagulation Protein Disease 12
Blood Coagulation Disorder 6

Classifications:



External Ids:

Disease Ontology 12 DOID:1247
ICD9CM 34 286
MeSH 44 D001778
NCIt 50 C2902
SNOMED-CT 67 64779008
ICD10 32 D68.9 O72.3
UMLS 70 C0005779 C0600503

Summaries for Blood Coagulation Disease

Disease Ontology : 12 A hematopoietic system disease that is characterized by abnormal blood clotting or bleeding.

MalaCards based summary : Blood Coagulation Disease, also known as blood coagulation disorders, is related to dysfibrinogenemia, congenital and blood platelet disease. An important gene associated with Blood Coagulation Disease is VWF (Von Willebrand Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs fluindione and Phenindione have been mentioned in the context of this disorder. Affiliated tissues include liver, whole blood and heart, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 73 Coagulopathy (also called a bleeding disorder) is a condition in which the blood's ability to coagulate... more...

Related Diseases for Blood Coagulation Disease

Diseases related to Blood Coagulation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 391)
# Related Disease Score Top Affiliating Genes
1 dysfibrinogenemia, congenital 32.9 THBD SERPINC1 F2
2 blood platelet disease 32.7 VWF U2AF1 THPO THBD SERPINC1 PF4
3 von willebrand's disease 32.6 VWF PF4 ITGA2B GP1BA F9 F8
4 hemophilia b 32.6 VWF SERPINC1 PF4 ICOSLG F9 F8
5 factor viii deficiency 32.6 VWF SERPINC1 ICOSLG F9 F8 F7
6 thrombophilia 32.6 VWF THBD SERPINC1 PF4 F9 F8
7 bernard-soulier syndrome 32.6 VWF THPO MPL ITGA2B GP1BA F9
8 factor xi deficiency 32.6 VWF THBD SERPINC1 F9 F8 F7
9 acquired von willebrand syndrome 32.6 VWF U2AF1 GP1BA F8 F7 F3
10 glanzmann thrombasthenia 1 32.6 VWF PF4 ITGA2B GP1BA F9 F8
11 afibrinogenemia, congenital 32.6 VWF SERPINC1 F8 F7 F3 F2
12 factor xiii deficiency 32.6 VWF SERPINC1 F8 F7 F3 F2
13 factor vii deficiency 32.6 SERPINC1 F9 F8 F7 F3 F2
14 factor v deficiency 32.6 VWF F9 F8 F7 F3 F2
15 factor xii deficiency 32.6 VWF SERPINC1 F9 F7 F3
16 factor x deficiency 32.6 F9 F7 F3 F2
17 prothrombin deficiency, congenital 32.3 SERPINC1 F2
18 hemophilia 31.5 F9 F8 F7
19 disseminated intravascular coagulation 31.5 VWF THBD SERPINC1 F9 F7 F3
20 hemophilia a 31.3 VWF F9 F8 F7 F3
21 arteriosclerosis 31.3 THBD SERPINC1 ITGA2B GP1BA F3
22 liver cirrhosis 31.1 THPO SERPINC1 F3 F2 ADAMTS13
23 heparin-induced thrombocytopenia 31.1 SERPINC1 PF4 F3
24 collagen disease 31.0 VWF THBD H2AC18
25 thrombocytopenia 30.9 VWF U2AF1 THPO THBD SERPINC1 PF4
26 vascular disease 30.9 VWF THBD SERPINC1 PF4 ITGA2B GP1BA
27 purpura 30.9 VWF THPO THBD SERPINC1 MPL ITGA2B
28 thrombophlebitis 30.9 VWF SERPINC1 F8 F7 F3 F2
29 thrombophilia due to activated protein c resistance 30.9 VWF THBD SERPINC1 F8 F3 F2
30 polycythemia vera 30.9 VWF U2AF1 THPO THBD PF4 MPL
31 hellp syndrome 30.9 VWF THBD SERPINC1 F3 F2 ADAMTS13
32 portal hypertension 30.9 VWF THPO F3 F2 ADAMTS13
33 thrombotic thrombocytopenic purpura 30.9 VWF THBD SERPINC1 F3 ADAMTS13
34 polycythemia 30.9 THPO SERPINC1 MPL F2
35 respiratory failure 30.8 THBD PF4 H2AC18 F3 F2 CCR6
36 varicose veins 30.8 VWF THBD SERPINC1 F2
37 myeloma, multiple 30.8 U2AF1 ICOSLG H2AC18 CSF3 CCR6
38 placental abruption 30.8 THBD SERPINC1 F2
39 meningococcemia 30.5 THBD SERPINC1
40 homocystinuria 30.1 THBD SERPINC1 F8
41 high molecular weight kininogen deficiency 11.0
42 scott syndrome 11.0
43 hereditary combined deficiency of vitamin k-dependent clotting factors 11.0
44 factor v and factor viii, combined deficiency of, 1 11.0
45 factor v and factor viii, combined deficiency of, 2 11.0
46 hemorrhagic disease 10.8 VWF THPO THBD SERPINC1 PF4 MPL
47 thrombosis 10.8 VWF THBD SERPINC1 PF4 ITGA2B GP1BA
48 myocardial infarction 10.8 VWF THBD SERPINC1 PF4 ITGA2B GP1BA
49 heart disease 10.7 VWF THBD SERPINC1 PF4 ITGA2B H2AC18
50 stroke, ischemic 10.7 VWF THBD SERPINC1 PF4 GP1BA F9

Graphical network of the top 20 diseases related to Blood Coagulation Disease:



Diseases related to Blood Coagulation Disease

Symptoms & Phenotypes for Blood Coagulation Disease

GenomeRNAi Phenotypes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCR6 CSF3 F9 GP1BA ITGA2B SERPINC1

MGI Mouse Phenotypes related to Blood Coagulation Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 ADAMTS13 CCR6 CSF3 F3 F8 F9
2 homeostasis/metabolism MP:0005376 9.83 ADAMTS13 CCR6 F2 F3 F7 F8
3 immune system MP:0005387 9.44 ADAMTS13 CCR6 CSF3 F2 F3 F8

Drugs & Therapeutics for Blood Coagulation Disease

Drugs for Blood Coagulation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
fluindione Approved, Investigational Phase 4 957-56-2
2
Phenindione Approved, Investigational Phase 4 83-12-5 4760
3
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
4
Protein C Approved Phase 4
5
Enoxaparin Approved Phase 4 9005-49-6 772
6
Dalteparin Approved Phase 4 9005-49-6
7
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
8
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Apixaban Approved Phase 4 503612-47-3 10182969
11 Coagulants Phase 4
12 Hydroxyethyl Starch Derivatives Phase 4
13 Vasopressins Phase 4
14 Arginine Vasopressin Phase 4
15 Deamino Arginine Vasopressin Phase 4
16 Fibrinolytic Agents Phase 4
17 polysaccharide-K Phase 4
18 Heparin, Low-Molecular-Weight Phase 4
19 calcium heparin Phase 4
20 Antirheumatic Agents Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Analgesics Phase 4
26 Serine Proteinase Inhibitors Phase 4
27 Antithrombins Phase 4
28 Antithrombin III Phase 4
29 HIV Protease Inhibitors Phase 4
30
protease inhibitors Phase 4
31 Factor Xa Inhibitors Phase 4
32 Ketorolac Tromethamine Phase 4
33 Thromboplastin Phase 4
34 Protamines Phase 4
35
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
36
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
37
Quinidine Approved, Investigational Phase 2, Phase 3 56-54-2 441074
38
Verapamil Approved Phase 2, Phase 3 52-53-9 2520
39
Tranexamic Acid Approved Phase 3 1197-18-8 5526
40
Fondaparinux Approved, Investigational Phase 3 104993-28-4
41
Polidocanol Approved Phase 2, Phase 3 9002-92-0
42
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
43
Vitamin K1 Approved, Investigational Phase 2, Phase 3 84-80-0 5284607
44
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8
45
Lysine Approved, Nutraceutical Phase 3 56-87-1 5962
46
Menadione Approved, Nutraceutical Phase 2, Phase 3 58-27-5 4055
47
Coumarin Experimental Phase 3 91-64-5 323
48 Menaquinone Investigational Phase 2, Phase 3 1182-68-9
49
Fibrinolysin Investigational Phase 3 9004-09-5
50 Quinidine gluconate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 396)
# Name Status NCT ID Phase Drugs
1 Study Using Plasma for Patients Requiring Emergency Surgery: A Randomized Pilot Trial of Early Plasma for Patients Undergoing Emergency Surgery for Hemorrhagic Shock Unknown status NCT01221389 Phase 4 Human Plasma
2 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
3 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
4 Profilatic Fibrinogen Concentrate Reduces Postoperative Bleeding in Pediatric Cardiac Surgery With Cardiopulmonary Bypass: Randomized Study Unknown status NCT03884725 Phase 4 Fibrinogen Concentrate
5 Placebo-Controlled, Randomized, Double-Blind Trial of Prophylactic Desmopressin in Heart Valve Surgery Unknown status NCT03343418 Phase 4 Desmopressin;Placebo
6 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
7 The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management Completed NCT00964353 Phase 4 Warfarin
8 A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery Completed NCT01487837 Phase 4 Human fibrinogen concentrate
9 Relationship of Edoxaban Plamsa Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis Completed NCT03666650 Phase 4 Edoxaban 60 MG
10 Early Administration of Fibrinogen Concentrate in Polytraumatized Patients With Thromboelastometry Suggestive of Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
11 The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass. Completed NCT02822599 Phase 4 RiaStAP;Saline
12 The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
13 An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
14 rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa Completed NCT00571584 Phase 4 activated recombinant human factor VII
15 Coagulopathy During Surgery for the Repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - Feasibility Study of the Use of Fibrinogen Concentrate by Infusion in Place of Fresh Frozen Plasma. Completed NCT00994045 Phase 4
16 Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients With Moderate or Severe Haemophilia A in India Completed NCT03449342 Phase 4 turoctocog alfa
17 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery. A Randomised Clinical Study Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
18 NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA® Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
19 Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy. Completed NCT00188747 Phase 4
20 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease. Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
21 Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients Recruiting NCT02777424 Phase 4 Prothrombin Complex Concentrate
22 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Recruiting NCT04360824 Phase 4 Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
23 Bivalirudin vs Heparin in Elderly Patients With Acute Coronary Syndrome Undergoing Elective Percutaneous Coronary Intervention Recruiting NCT04046029 Phase 4 Bivalirudin;Heparin
24 Prospective, Multi-center, Randomized, Parallel-control, Superiority Study Comparing Administration of Clotting Factor Concentrates With a Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients. Recruiting NCT04534751 Phase 4
25 Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
26 Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery Not yet recruiting NCT03805607 Phase 4 Ketorolac Tromethamine 30 MG/ML;Placebos
27 Randomized Trial of Reinforcement Learning for the Dosing of Warfarin Not yet recruiting NCT03962400 Phase 4
28 A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) Not yet recruiting NCT04128254 Phase 4 Apixaban Oral Tablet
29 Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión Terminated NCT01919840 Phase 4
30 A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Withdrawn NCT02774317 Phase 4
31 PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care Withdrawn NCT00377143 Phase 4 Warfarin Dosing
32 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures Unknown status NCT02637427 Phase 3
33 Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT) Unknown status NCT02561026 Phase 3
34 Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) Unknown status NCT03570281 Phase 2, Phase 3 Edoxaban;Enoxaparin
35 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
36 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
37 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding Completed NCT00708435 Phase 3
38 A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy Completed NCT01029340 Phase 3
39 Restrictive Versus Liberal Fresh Frozen Plasma Transfusion Prior to Low-Risk Invasive Procedures in Hospitalized Patients. Completed NCT00953901 Phase 3 Fresh Frozen Plasma Transfusion
40 Cooperative Study of Factor VIII Inhibitors Completed NCT00000582 Phase 3 factor ix
41 A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia Completed NCT02690714 Phase 2, Phase 3
42 A Randomized Trial to Evaluate Freezed-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients Completed NCT02750150 Phase 3 Freezed-dried plasma;Fresh-frozen plasma
43 A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency Completed NCT00713648 Phase 3 catridecacog
44 A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency. Safety Extension Trial to F13CD-3760 Completed NCT01253811 Phase 3 catridecacog
45 A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency Completed NCT01230021 Phase 3 catridecacog
46 Interest of Pre-hospital Administration of Lyophilized Plasma to Prevent or Treat Coagulopathy Associated With Post-traumatic Hemorrhagic Shock (PREHO-PLYO Study ) Completed NCT02736812 Phase 3
47 A Multi-centre, Open-label, Non-controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects With Haemophilia A. Sub-trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding During Surgical Procedures in Subjects With Haemophilia A Completed NCT00840086 Phase 3 turoctocog alfa
48 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure Completed NCT00803101 Phase 3
49 A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A Completed NCT01731600 Phase 3 turoctocog alfa pegol
50 A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B Completed NCT01333111 Phase 3 nonacog beta pegol;nonacog beta pegol;nonacog beta pegol

Search NIH Clinical Center for Blood Coagulation Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Tranexamic Acid
TRANEXAMIC ACID PWDR

Cochrane evidence based reviews: blood coagulation disorders

Genetic Tests for Blood Coagulation Disease

Anatomical Context for Blood Coagulation Disease

MalaCards organs/tissues related to Blood Coagulation Disease:

40
Liver, Whole Blood, Heart, Eye, Prostate, Thyroid, Kidney

Publications for Blood Coagulation Disease

Articles related to Blood Coagulation Disease:

(show top 50) (show all 454)
# Title Authors PMID Year
1
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. 6
31064749 2019
2
Patient-Specific Modelling of Blood Coagulation. 61
33772645 2021
3
Should We Postpone Elective Cardiovascular Procedures and Percutaneous Coronary Interventions During the COVID-19 Pandemic? 61
33635255 2021
4
Clinical and Therapeutic Aspects of Brazilian Native Bothrops Envenomation in Nine Horses. 61
33077082 2020
5
Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy. 61
32899532 2020
6
Angina bullosa hemorrhagica, an uncommon oral disorder. Report of 4 cases. 61
32509235 2020
7
Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review. 61
32461798 2020
8
Study of the Association Between microRNA (miR-25T>C, miR-32C>A, miR-125C>T, and miR-222G>T) Polymorphisms and the Risk of Recurrent Pregnancy Loss in Korean Women. 61
32224893 2020
9
Implications of Hemostasis Disorders in Patients with Critical Limb Ischemia-An In-Depth Comparison of Selected Factors. 61
32121363 2020
10
Coagulation System Disorders and Thrombosis Prophylaxis During Laparoscopic Fundoplications. 61
31517745 2019
11
Contribution of nascent cohesive fiber-fiber interactions to the non-linear elasticity of fibrin networks under tensile load. 61
31152942 2019
12
[Blood Coagulation Disorders During ECMO and LVAD Therapy]. 61
31212331 2019
13
Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement. 61
31144420 2019
14
Distinct plasma proteomic changes in male and female African American stroke patients. 61
31149323 2019
15
[The condition of the hemostatic system in acute severe peritonitis during remaxol therapy]. 61
30855593 2019
16
In vitro anticoagulant effect of Crassocephalum crepidioides leaf methanol extract and fractions on human blood. 61
31564995 2019
17
Suprachoroideal haemorrhage in postoperative period of antiglaucoma surgery, case report. 61
31537078 2019
18
[A case of congenital bile acid synthesis disorder type 2 and literature review]. 61
30298497 2018
19
The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions. 61
30005228 2018
20
Hemorrhagic Events in Adult Celiac Disease Patients. Case Report and Review of the Literature. 61
29557421 2018
21
Microbial serine protease inhibitors and their therapeutic applications. 61
28970170 2018
22
Correlations between lipid metabolism indices in patients with hypertension and hypothyroidism. 61
29729156 2018
23
Thrombosis in Thyroid Cancer. 61
29696039 2018
24
A User-Friendly App for Blood Coagulation Disorders. 61
29380340 2018
25
Hemostasis in Overt and Subclinical Hyperthyroidism. 61
29201071 2017
26
Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders. 61
29026409 2017
27
Thromboelastographic profile of goat blood after the experimental injury of the femoral artery and use of QuikClot gauze and Celox gauze dressings. 61
28525329 2017
28
Measuring coagulation in burns: an evidence-based systematic review. 61
29799542 2017
29
Novel combined strategy of obstetric haemorrhage management during caesarean section using intrauterine balloon tamponade. 61
26625194 2017
30
Possibly propylthiouracil-induced antineutrophilic cytoplasmic antibody-associated vasculitis manifested as blood coagulation disorders: A case report. 61
27741122 2016
31
Treatment of Coagulopathy Related to Hepatic Insufficiency. 61
27635482 2016
32
Biomedical and Catalytic Applications of Gold and Silver-Gold Alloy Nanoparticles Biosynthesized Using Cell-Free Extract of Bacillus Safensis LAU 13: Antifungal, Dye Degradation, Anti-Coagulant and Thrombolytic Activities. 61
27164598 2016
33
Protease-activated receptors - biology and role in cancer. 61
27383574 2016
34
Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics. 61
26116831 2016
35
A portable blood plasma clot micro-elastometry device based on resonant acoustic spectroscopy. 61
26233406 2015
36
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain. 61
26051726 2015
37
[Anesthesia and perioperative management for cesarean section in patient with factor XI deficiency: a case report]. 61
24743832 2014
38
A conformational investigation of propeptide binding to the integral membrane protein γ-glutamyl carboxylase using nanodisc hydrogen exchange mass spectrometry. 61
24512177 2014
39
Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa. 61
24412029 2014
40
[Features of coagulative blood potential disorder in acute constitutional inflammatory response of septic tubo-ovarian formations]. 61
25971120 2014
41
[Overview--Recent therapeutic strategy for blood coagulation disorders]. 61
24492038 2014
42
TURP and PVP treatments are really similar? From subjective feeling to objective data. Pilot study (proof of concept) prospective randomized trial. 61
23427748 2012
43
Quantification of circulating D-dimer by peptide immunoaffinity enrichment and tandem mass spectrometry. 61
22788854 2012
44
[Bundle program of treatment for acute severe type high altitude disease]. 61
22748458 2012
45
[Neonatal renal vein thrombosis in a heterozygous carrier of both factor V Leiden and the MTHFR gene mutation]. 61
22361411 2012
46
[Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique?]. 61
22154448 2012
47
Chapter 9: Analyses using disease ontologies. 61
23300417 2012
48
Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge. 61
21633664 2011
49
Malignant tumours of colon and rectum from the blood clotting view. 61
22180990 2011
50
D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer. 61
21391740 2011

Variations for Blood Coagulation Disease

ClinVar genetic disease variations for Blood Coagulation Disease:

6 (show all 32)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 F9 NM_000133.3(F9):c.276del (p.Asp93fs) Deletion Pathogenic 627047 rs1603264300 GRCh37: X:138619543-138619543
GRCh38: X:139537384-139537384
2 VWF NM_000552.4(VWF):c.4453del (p.Val1485fs) Deletion Pathogenic 100360 rs61750095 GRCh37: 12:6128131-6128131
GRCh38: 12:6018965-6018965
3 VWF NM_000552.4(VWF):c.7080C>A (p.Cys2360Ter) SNV Pathogenic 627363 rs111597150 GRCh37: 12:6092317-6092317
GRCh38: 12:5983151-5983151
4 F8 NM_000132.3(F8):c.6685C>T (p.Leu2229Phe) SNV Pathogenic 627359 rs1603431508 GRCh37: X:154090031-154090031
GRCh38: X:154861756-154861756
5 F7 NM_019616.4(F7):c.781C>T (p.Arg261Trp) SNV Pathogenic 627147 rs779589651 GRCh37: 13:113772768-113772768
GRCh38: 13:113118454-113118454
6 F8 NM_000132.3(F8):c.5123G>A (p.Arg1708His) SNV Pathogenic 10266 rs111033614 GRCh37: X:154156942-154156942
GRCh38: X:154928667-154928667
7 VWF NM_000552.4(VWF):c.7988G>C (p.Arg2663Pro) SNV Likely pathogenic 372760 rs149834874 GRCh37: 12:6061684-6061684
GRCh38: 12:5952518-5952518
8 F9 NM_000133.3(F9):c.835G>A (p.Ala279Thr) SNV Likely pathogenic 216926 rs137852247 GRCh37: X:138643011-138643011
GRCh38: X:139560852-139560852
9 VWF NM_000552.4(VWF):c.5278G>A (p.Val1760Ile) SNV Likely pathogenic 100422 rs61750604 GRCh37: 12:6125715-6125715
GRCh38: 12:6016549-6016549
10 VWF NM_000552.4(VWF):c.5851A>G (p.Thr1951Ala) SNV Likely pathogenic 619971 rs144072210 GRCh37: 12:6105380-6105380
GRCh38: 12:5996214-5996214
11 F8 NM_000132.3(F8):c.2149C>T (p.Arg717Trp) SNV Likely pathogenic 10245 rs137852435 GRCh37: X:154159916-154159916
GRCh38: X:154931641-154931641
12 VWF NM_000552.4(VWF):c.2561G>A (p.Arg854Gln) SNV Likely pathogenic 296 rs41276738 GRCh37: 12:6143978-6143978
GRCh38: 12:6034812-6034812
13 F8 NM_000132.3(F8):c.6932C>A (p.Pro2311His) SNV Likely pathogenic 627123 rs1047644991 GRCh37: X:154065996-154065996
GRCh38: X:154837721-154837721
14 F7 NM_019616.4(F7):c.1094T>C (p.Met365Thr) SNV Likely pathogenic 627214 rs1595080725 GRCh37: 13:113773081-113773081
GRCh38: 13:113118767-113118767
15 VWF NM_000552.4(VWF):c.3916C>T (p.Arg1306Trp) SNV Likely pathogenic 288 rs61749384 GRCh37: 12:6128668-6128668
GRCh38: 12:6019502-6019502
16 VWF NM_000552.4(VWF):c.2447G>A (p.Arg816Gln) SNV Likely pathogenic 100223 rs62643634 GRCh37: 12:6145653-6145653
GRCh38: 12:6036487-6036487
17 VWF NM_000552.5(VWF):c.4196G>A SNV Likely pathogenic 293 rs1800382 GRCh37: 12:6128388-6128388
GRCh38: 12:6019222-6019222
18 F8 NM_000132.3(F8):c.599A>G (p.Glu200Gly) SNV Likely pathogenic 449370 rs782158761 GRCh37: X:154221213-154221213
GRCh38: X:154992938-154992938
19 F7 NM_019616.4(F7):c.1024C>T (p.Arg342Trp) SNV Likely pathogenic 626967 rs750980786 GRCh37: 13:113773011-113773011
GRCh38: 13:113118697-113118697
20 VWF NM_000552.4(VWF):c.3314C>A (p.Ala1105Asp) SNV Likely pathogenic 626953 rs1591866220 GRCh37: 12:6132862-6132862
GRCh38: 12:6023696-6023696
21 F9 NM_000133.3(F9):c.1067G>T (p.Trp356Leu) SNV Likely pathogenic 627201 rs1479241411 GRCh37: X:138643911-138643911
GRCh38: X:139561752-139561752
22 VWF NM_000552.4(VWF):c.6553C>T (p.Arg2185Trp) SNV Uncertain significance 627354 rs569962285 GRCh37: 12:6103073-6103073
GRCh38: 12:5993907-5993907
23 VWF NM_000552.4(VWF):c.4473G>C (p.Lys1491Asn) SNV Uncertain significance 627073 rs1591862624 GRCh37: 12:6128111-6128111
GRCh38: 12:6018945-6018945
24 VWF NM_000552.4(VWF):c.6479A>G (p.Tyr2160Cys) SNV Uncertain significance 627112 rs779764302 GRCh37: 12:6103147-6103147
GRCh38: 12:5993981-5993981
25 F9 NM_000133.3(F9):c.740A>C (p.Lys247Thr) SNV Uncertain significance 627124 rs1603267173 GRCh37: X:138642916-138642916
GRCh38: X:139560757-139560757
26 VWF NM_000552.4(VWF):c.7849C>A (p.Leu2617Met) SNV Uncertain significance 627383 rs371948517 GRCh37: 12:6076690-6076690
GRCh38: 12:5967524-5967524
27 F8 NM_000132.3(F8):c.5587-98G>A SNV Uncertain significance 627092 rs1603432993 GRCh37: X:154132897-154132897
GRCh38: X:154904622-154904622
28 F8 NM_000132.3(F8):c.6751G>A (p.Val2251Met) SNV Uncertain significance 627114 rs1603431480 GRCh37: X:154088856-154088856
GRCh38: X:154860581-154860581
29 F8 NM_000132.3(F8):c.6901-725T>C SNV Uncertain significance 627120 rs1393847621 GRCh37: X:154066752-154066752
GRCh38: X:154838477-154838477
30 F8 NM_000132.3(F8):c.788-14T>G SNV Uncertain significance 627137 rs1603435417 GRCh37: X:154197841-154197841
GRCh38: X:154969566-154969566
31 VWF NM_000552.4(VWF):c.3686T>G (p.Val1229Gly) SNV Uncertain significance 100274 rs61749367 GRCh37: 12:6128898-6128898
GRCh38: 12:6019732-6019732
32 VWF NM_000552.4(VWF):c.3692A>C (p.Asn1231Thr) SNV Uncertain significance 100275 rs61749368 GRCh37: 12:6128892-6128892
GRCh38: 12:6019726-6019726

Expression for Blood Coagulation Disease

Search GEO for disease gene expression data for Blood Coagulation Disease.

Pathways for Blood Coagulation Disease

Pathways related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 VWF THPO THBD SERPINC1 PF4 MPL
2
Show member pathways
12.64 THBD SERPINC1 F9 F8 F7 F3
3 11.85 VWF ITGA2B GP1BA F2
4 11.78 THPO MPL ITGA2B GP1BA CSF3
5 11.77 VWF THBD SERPINC1 F9 F8 F7
6 11.73 THPO ITGA2B GP1BA CSF3
7
Show member pathways
11.73 VWF THPO MPL ITGA2B GP1BA F2
8
Show member pathways
11.52 VWF THBD SERPINC1 PF4 GP1BA F9
9 11.36 VWF ITGA2B F2
10 10.76 F9 F7 F2
11 10.62 VWF GP1BA
12 10.49 VWF GP1BA

GO Terms for Blood Coagulation Disease

Cellular components related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 VWF THPO SERPINC1 PF4 F9 F8
2 cell surface GO:0009986 9.87 THBD MPL ITGA2B GP1BA F3 CCR6
3 external side of plasma membrane GO:0009897 9.8 THBD ITGA2B ICOSLG F2 CCR6
4 endoplasmic reticulum lumen GO:0005788 9.73 SERPINC1 F9 F8 F7 F2 ADAMTS13
5 platelet alpha granule lumen GO:0031093 9.61 VWF PF4 F8
6 collagen-containing extracellular matrix GO:0062023 9.5 VWF SERPINC1 PF4 F9 F7 F3
7 extracellular space GO:0005615 9.44 VWF THPO THBD SERPINC1 PF4 GP1BA
8 serine-type peptidase complex GO:1905286 9.37 F7 F3

Biological processes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.81 F9 F8 F7 F2
2 positive regulation of protein kinase B signaling GO:0051897 9.8 THPO F7 F3 CSF3
3 platelet activation GO:0030168 9.73 VWF PF4 GP1BA F8 F2 ADAMTS13
4 protein processing GO:0016485 9.72 F7 F3 ADAMTS13
5 regulation of megakaryocyte differentiation GO:0045652 9.7 PF4 ITGA2B GP1BA
6 platelet degranulation GO:0002576 9.67 VWF PF4 ITGA2B F8
7 blood coagulation GO:0007596 9.65 VWF THBD SERPINC1 GP1BA F9 F8
8 platelet aggregation GO:0070527 9.63 MPL ITGA2B GP1BA
9 positive regulation of positive chemotaxis GO:0050927 9.58 F7 F3
10 negative regulation of fibrinolysis GO:0051918 9.57 THBD F2
11 cytolysis by host of symbiont cells GO:0051838 9.56 F2 CFHR2
12 blood coagulation, intrinsic pathway GO:0007597 9.55 VWF GP1BA F9 F8 F2
13 negative regulation of platelet activation GO:0010544 9.54 THBD F2
14 regulation of blood coagulation GO:0030193 9.5 SERPINC1 GP1BA F2
15 thrombopoietin-mediated signaling pathway GO:0038163 9.48 THPO MPL
16 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.43 F7 F3
17 blood coagulation, extrinsic pathway GO:0007598 9.4 F7 F3
18 hemostasis GO:0007599 9.32 VWF THBD SERPINC1 GP1BA F9 F8

Molecular functions related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 VWF U2AF1 THBD SERPINC1 PF4 MPL
2 endopeptidase activity GO:0004175 9.33 F9 F7 ADAMTS13
3 serine-type endopeptidase activity GO:0004252 8.92 F9 F7 F3 F2

Sources for Blood Coagulation Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....